Abstract 473P
Background
The combination of endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDKi) for ER+HER2neg metastatic breast cancer has been associated with 13% of drug-induced liver injury (DILI). In a previous work (Vega et al, ESMO Breast 2023), we identified 26 cases of DILI (5.5%), defined as AST/ALT elevation ≥G2, among 472 patients (pts) treated. Here, we present a case-control study to evaluate the clinical factors associated with DILI.
Methods
The case-control study includes i) 89 pts without DILI randomly selected and retrospectively analyzed (control group) and ii) 26 cases with DILI previously reported. 15 potential predictive factors were evaluated either individually or in combination. Baseline liver steatosis was based on computed tomography reports. To study the association with DILI, odds ratios (ORs) were calculated using logistic regression.
Results
The main characteristics of the 115 pts are shown in the table. In the univariate analysis, no baseline risk factor alone was statistically associated with DILI, steatosis and AST/ALT baseline elevation had the best results (p<0.15). However, the combination of steatosis and pre-menopause status (n=9, 7.8%) significantly increased the risk to 66.7% vs 19% (20/105) (OR=8.6, 95% CI 2.1-43.6; p=0.004). No other variables, including cardiovascular risk factors, ET partner or liver metastasis predicted DILI development.
Table: 473P
Baseline characteristics of cases and control
Cases n=26 | Controls n=89 | |
Palbociclib | 8 | 32 |
Abemaciclib | 9 | 29 |
Ribociclib | 9 | 28 |
Age (median) | 61 | 60 |
Overweight | 33% | 36% |
Obesity | 26% | 28% |
Pre-Menopause | 54% | 35% |
Hypertension | 27% | 27% |
Diabetes mellitus | 4% | 11% |
Dyslipidemia | 31% | 29% |
Aromatase inhibitor | 65% | 57% |
Fulvestrant | 35% | 43% |
Liver metastasis | 27% | 30% |
Steatosis | 31% | 15% |
Baseline ALT or AST >35 IU/mL | 36% | 17% |
Conclusions
In our case-control series, the combination of premenopausal status and steatosis was the strongest predictor for CDKi-related DILI. Our findings suggest that metabolic changes due to ovarian factor suppression cooperate with CDKi to induce DILI in pts with underlying steatosis. A prospective study is needed to validate these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
C. Saura Manich: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Daiichi Sankyo, Eisai, Exact Sciences, Exeter Pharma, F. Hoffmann - La Roche Ltd, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Philips, Piere Fabre, PintPharma, Puma, Roche Farma, Sanofi-Aventis, SeaGen, Zymeworks, Genentech, Innoup, Millenium, Pharmalex Spain SLU; Financial Interests, Personal, Other, SC: Byondis B.V., Glaxo, Macrogenics, Menarini, Merus, Synthon Biopharpaceuticals; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Cytomx Therapeutics, Daiichi Sankyo, Eli Lilly and Company, F. Hoffmann-La RocheLtd, Genentech, GSK, Immunomedics, Innoup Farma, Macrogenics, Menarini Ricerche, Merus, Novartis, Pfizer, Puma, Roche, Sanofi-Aventis, Seattle Genetics; Financial Interests, Institutional, Coordinating PI: Byondis B.V.; Non-Financial Interests, Member: Spanish Society of Medical Oncology (SEOM), American Society for Clinical Oncology (ASCO), Geicam (Spanish Breast Cancer Research Group), European Society for Medical Oncology (ESMO), Sinology Society of the Official College of Physicians of Barcelona (COMB); Non-Financial Interests, Member, Junta Directiva y Comité Científico: SOLTI group (Academic research group in breast cancer). M. Bellet Ezquerra: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, Lilly, Stemline-Menarini; Other, Speaker's Bureau and Travel Expenses: Pfizer; Other, Speaker's Bureau: Novartis, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04